Startups
Lunac Therapeutics
Develops oral and intravenous anticoagulants that inhibit activated Factor XII to prevent dangerous blood clots while aiming to avoid the bleeding risk of existing treatments. The company is a University of Leeds spinout.
Team
 Alan NaylorAdvisor |
Helen PhilippouScientific Founder and Board Member |
Julian HowellChief Executive Officer |
Mary CanningBoard Member |
 Mervyn TurnerChairman |
Peter FinanBoard Member |
Richard BrooksHead of Finance |
Richard FosterScientific Founder |
Sarah JarminBoard Member |